Adjunctive Therapies: Photodynamic, Electromagnetic, Radioimmunotherapy, and Angiogenesis Inhibitors
The combined worldwide market for four categories of adjunctive therapies is estimated at $1.7 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 39.2% to $8.8 billion in 2009.
Two of the four categories, antiangiogenic drugs and radioimmunotherapy, will see AAGRs exceeding 50% from 2004 to 2009.
Antiangiogenic drugs surpassed photodynamic therapies as the largest category in 2004 and will represent 71% of the market in 2009.
Radioimmunotherapy will grow at the second highest rate (44.1%) but will remain the smallest category throughout the period.
While great strides have been made in the treatment of disease and trauma, truly effective therapy remains wanting in most cases, especially for cancer but in other diseases and conditions as well. It has become standard practice in the treatment of many diseases as well as in surgical procedures to combine therapeutic approaches to achieve the greatest benefit.
A number of therapies adjunctive to traditional drug and surgical treatments are emerging as standard protocol in several therapeutic areas. This timely BCC report provides an overview of these adjunctive therapies, delineates how they are used, the impact they are having and the global markets they are creating. Adjunctive therapies discussed in this report include photodynamic therapy (PDT), radioimmunotherapy, bioelectromagnetic therapy (specifically bone growth stimulation devices) and angiogenesis inhibition. These categories represent treatments that are rapidly emerging and for which the markets are expected to grow exponentially through the current decade.
PDT involves administering a photosensitive drug to the patient and then applying light of a specific wavelength matched to the photoactive qualities of the drug. Radioimmunotherapy is a form of cancer therapy that uses biological products linked to radioactive substances. Bioelectromagnetic therapy uses external devices that apply low-level electromagnetic fields externally to the body for healing purposes. Finally, angiogenesis inhibition controls the creation of blood vessels feeding cancer cells.
SCOPE OF STUDY
The report contains:
- An overview of the four categories
- Descriptions of the technologies involved and how these differ from existing and emerging technologies
- Discussion of the technology approaches undertaken by the various competitors, how current and emerging products are used, and industry and end-user response to these products
- Analysis of regulatory issues and legislation affecting use and marketing of products
- Market forecasts through 2009 for each category
- Profiles of selected competitors in each category.
The base year for this study is 2003. Market figures are based on revenues at the manufacturers' level and are projected at 2004-dollar value (i.e., inflation is not computed into the projection figures).
Data to prepare this study was derived from information obtained from interviews with management at companies competing in the various categories of adjunctive therapies or which have products in development that will compete in the four categories covered in the report. In addition, interviews were conducted with physicians and other professionals to gain insight into clinical assessment and usage of and preference for different therapeutics and technologies. Key information from literature was used to obtain expert opinions on commercial potential and market sizes from industry professionals.
Lynn Gray has been a research analyst in biotechnology and life sciences since 1989 and with BCC since 1996. During that time, she has authored numerous reports in the biomedical field, 20 for BCC alone. She has a BA from the University of California, Riverside, 1973.